Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03794492|
Recruitment Status : Active, not recruiting
First Posted : January 7, 2019
Last Update Posted : February 18, 2020
|Condition or disease||Intervention/treatment||Phase|
|Kidney Transplant Patients||Drug: Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap. Drug: Tacrolimus Drug: Methylprednisolone/prednisone Drug: Simulect® (Basiliximab)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||158 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome: Open-label, Multi-center, Single Arm, Phase 4 Trial (DoSAKOM)|
|Actual Study Start Date :||March 31, 2018|
|Estimated Primary Completion Date :||March 21, 2022|
|Estimated Study Completion Date :||November 29, 2022|
Experimental: Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.
Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.
Drug: Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.
Mycophenolate mofetil 1,000 ~ 2,000mg
Other Name: Mycophenolate mofetil 1,000 ~ 2,000mg
Drug: Simulect® (Basiliximab)
- DSA(Donor-specific Anti-HLA Antibody) [ Time Frame: 36 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03794492
|Korea, Republic of|
|Ajou University Hospital|
|Suwan, Korea, Republic of|
|Study Chair:||Chang-Kwan Oh, Ph.D||Ajou University School of Medicine|